

Olaratumab

Cat. No.:	HY-P9922
CAS No.:	1024603-93-7
Target:	PDGFR
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFR α) human monoclonal IgG1 antibody with antitumor activity ^[1] .
In Vitro	IMC-3G3 (100 μ g/mL, 72 h) blocked PDGFR α phosphorylation in SKOV3-ip1 cells. And the combined treatment of IMC-3G3 and docetaxel significantly induced apoptosis in SKOV3-ip1 and HeyA8 cell lines ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	IMC-3G3 (i.p., 40 mg/kg, three times per week, 6 weeks) in SKOV3-ip1 tumor-bearing mice, compared with the control group, IMC-3G3 treatment alone had no obvious anti-tumor effect, while in HeyA8 tumor-bearing mice, IMC-3G3 monotherapy showed a significant anti-tumor effect compared with the control group, with a tumor reduction rate of 62% ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Koji Matsuo, et al. Platelet-derived growth factor receptor alpha (PDGFR α) targeting and relevant biomarkers in ovarian carcinoma. Gynecol Oncol. 2014 Jan;132(1):166-75.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA